Ligand Pharmaceuticals Incorporated (LGND)

CenterBook Partners LP lowered its stake in shares of Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) by 52.2% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 6,434 shares of the biotechnology company's stock after selling 7,033 shares during the quarter. CenterBook

JUPITER, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026.

JUPITER, Fla., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, which will be held virtually, on February 25, 2026 at 10:00 a.m.

Acuitas Investments LLC boosted its position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) by 1,922.9% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 402,494 shares of the biotechnology company's stock after acquiring an additional 382,597 shares during the quarter. Ligand

Chicago Capital LLC lowered its position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) by 0.6% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 568,611 shares of the biotechnology company's stock after selling 3,214 shares during the quarter. Ligand Pharmaceuticals comprises about

Ligand Pharmaceuticals Incorporated (LGND) Analyst/Investor Day Transcript

Introduces 2026 full year revenue guidance of $245 million to $285 million, an approximately 15% increase in core revenue growth over 2025, royalty revenue of $200 to $225 million, a 40% increase over 20251, and core adjusted earnings per diluted share of $8.00 to $9.002 Increases 5-year royalty receipt outlook driven by Filspari, Ohtuvayre, and Zelsuvmi; expects to meet or exceed 23% compound annual growth rate $1 billion in deployable capital expected to drive long-term royalty revenue growth JUPITER, Fla., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) will host its Investor Day in New York City today.

Exploring Tweedy Browne (Trades, Portfolio)'s Recent 13F Filing and Investment Adjustments Tweedy Browne (Trades, Portfolio) recently submitted its 13F filing

Delaware-based Ashford Capital Management sold 58,097 shares of Ligand Pharmaceuticals for an estimated $8.9 million in the third quarter. The transaction value equaled about 1% of 13F reportable assets under management at quarter-end.

Envestnet Asset Management Inc. boosted its holdings in Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) by 2.9% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 27,377 shares of the biotechnology company's stock after purchasing an additional 769 shares during the period.

Insights from Private Capital (Trades, Portfolio)'s Third Quarter 2025 13F Filing Private Capital (Trades, Portfolio) recently submitted its 13F filing for the

Ligand Pharmaceuticals (LGND) continues to deliver strong returns, with shares up approximately 74% since my last 'Buy' rating in June 2025. LGND's attractive royalty-based business model remains a key driver of its outperformance and future investment appeal. This article evaluates LGND's ongoing investment prospects in light of its recent substantial price appreciation.

Ligand Pharmaceuticals Incorporated ( LGND ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Melanie Herman Todd Davis - CEO & Director Lauren Hay Octavio Espinoza - Chief Financial Officer Conference Call Participants Trevor Allred - Oppenheimer & Co. Inc., Research Division Jayed Momin - Stifel, Nicolaus & Company, Incorporated, Research Division Sahil Dhingra - RBC Capital Markets, Research Division Presentation Operator Thank you for standing by. Welcome to Ligand Third Quarter 2025 Earnings Call.

Third quarter performance driven by strong portfolio royalty revenue growth of  47% 2025 full year revenue guidance increased to $225 million - $235 million (previously $200 million - $225 million) and adjusted earnings per diluted share 1 increased to $7.40 - $7.65 (previously $6.70 - $7.00) Conference call begins at 8:30 a.m. Eastern Time today JUPITER, Fla.

JUPITER, Fla., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in the following upcoming investor conferences: UBS Global Healthcare Conference (Palm Beach Gardens): Management will participate in one-on-one meetings on November 10, 2025.

Ligand Pharmaceuticals (LGND) (Health Care, Pharmaceuticals) shares rose after announcing adjusted earnings per share that came in ahead of consensus. Acadian Asset Management (AAMI) (Financials, Asset Management & Custody Banks) saw another quarter of better-than-expected flows, driving earnings upside relative to expectations. SI-Bone (SIBN) (Health Care, Health Care Equipment) was weaker despite reporting a marginal beat on revenue and expectations of improved profitability.